The clinical trial failure dilemma. What constitutes clinical trial failure is a matter of perspective. For sponsors, the ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses the most prominent challenges he is seeing in the space right now ...

These were across five common KRIs (adverse events, serious adverse events, screen failure, early termination, and data entry ...

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving ...

As oncology research centers scale eSource adoption, the field is shifting toward a fully digital, clinical trial ecosystem.

Why investing in truly effective training from the outset can pay off exponentially for clinical teams—and serve as a ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

Many clinical researchers lament the rise of misinformation and yearn for the orderly days of fewer, more authoritative ...

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key questions each clinical trial stakeholder must now navigate.

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, talks the current landscape of sustainability in clinical trials and how stakeholders are beginning to pay more attention ...

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights where regulatory agencies currently stand on sustainability in clinical trials and how pharma companies are ...